NDAINJECTIONINJECTABLEPriority Review
Approved
Apr 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
4/8 — Partial
Priority Review
VISUDYNE (verteporfin for injection) by Bausch + Lomb is photoabsorption [moa]. Approved for age-related macular degeneration. First approved in 2000.
Drug data last refreshed 18h ago
Mechanism of Action
Photoabsorption
Pharmacologic Class:
Photoenhancer
Indications (1)
Clinical Trials (9)
Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
Started May 2007
31 enrolled
Age-Related MaculopathyChoroidal Neovascularization
Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
Started Feb 2007
10 enrolled
Age-Related Macular Degeneration
Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
Started Jan 2007
7 enrolled
Age-Related Macular Degeneration
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
Started Oct 2006
20 enrolled
Age Related Macular Degeneration
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
Started May 2006
22 enrolled
Age Related Macular DegenerationChoroidal NeovascularizationMacular Edema
Worked on VISUDYNE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.